At last, Taro Pharma is to get listed back on a major stock exchange, NYSE. Part of the initial investment thesis was once Taro was listed on a major exchange other investors could buy the shares. These new investors would realize the disconnect between the stock price and the business fundamentals.
I would believe this also an indication that Sun Pharma is unlikely to be successful in its acquisition of the minority stake of Taro at a huge discount.